NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for F...(d revenue ...),Health

Date:11/5/2009

d revenue 32,766 29,634 Long-term debt 37,226 21,054 Other long-term liabilities 2,008 1,892 ----- ----- Total liabilities 100,055 89,619 Commitments and contingencies Stockholders' equity: Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding, as of September 30, 2009 and December 31, 2008 - - Common stock: par value $0.001, 100,000,000 shares authorized; 46,695,539 and 46,548,585 shares issued and outstanding, as of September 30, 2009 and December 31, 2008, respectively 47 47 Additional paid-in capital 362,934 355,266 Accumulated deficit (268,037) (233,247) Accumulated other comprehensive income 471 381 --- --- Total stockholders' equity 95,415 122,447 ------ ------- Total liabilities and stockholders' equity $195,470 $212,066 ======== ======== NxStage Medical, Inc. Cash Flows from Operating Activities (in thousands) (unaudited) Nine Months Ended September 30, -------------
'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress